CONSTELLA linaclotide 290 microgram hard capsule bottle

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

linaclotide, Quantity: 0.29 mg

Disponível em:

Abbvie Pty Ltd

Forma farmacêutica:

Capsule, hard

Composição:

Excipient Ingredients: calcium chloride dihydrate; hypromellose; microcrystalline cellulose; leucine; titanium dioxide; potable water; Gelatin; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; Shellac; sulfuric acid

Via de administração:

Oral

Unidades em pacote:

4, 30

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

CONSTELLA is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (IBS-C) and ? chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.

Resumo do produto:

Visual Identification: White to off-white opaque body and cap, size '2' hard capsules with "FL 290" printed in grey ink on the cap; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status de autorização:

Registered

Data de autorização:

2019-06-18